Celecoxib, a specific PTGS2 inhibitor, has been shown to reduce the growth of both K562 and primary CML cells and induce apoptosis in a dose-dependent manner. This evidence concerns the gene PTGS2 and chronic myelogenous leukemia, BCR-ABL1 positive.